Invention Grant
- Patent Title: Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
-
Application No.: US16494962Application Date: 2018-03-03
-
Publication No.: US11879014B2Publication Date: 2024-01-23
- Inventor: Anne Goubier , Josephine Salimu , Kevin Moulder , Beatriz Goyenechea Corzo , Pascal Merchiers , Sergio Quezada , Karl Peggs , Frederick Arce Vargas , Isabelle Solomon
- Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
- Applicant Address: GB Hertfordshire
- Assignee: Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- Current Assignee: Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- Current Assignee Address: GB Hertfordshire; GB London
- Agency: Choate, Hall & Stewart LLP
- Agent Brenda Herschbach Jarrell; Michael L. Vetter
- Priority: EP 161717 2017.03.17 GB 10879 2017.07.06 GB 14429 2017.09.07
- International Application: PCT/EP2018/056312 2018.03.03
- International Announcement: WO2018/167104A 2018.09.20
- Date entered country: 2019-09-17
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/00 ; C07K14/55 ; A61K45/06
Abstract:
The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
Public/Granted literature
- US20200010554A1 FC-OPTIMIZED ANTI-CD25 FOR TUMOR SPECIFIC CELL DEPLETION Public/Granted day:2020-01-09
Information query
